发布求助
文献互助 智能选刊 最新文献

Annual review of medicine最新文献

筛选
英文 中文
Kawasaki Disease Vasculitis: From Diagnosis to New Concepts in Pathophysiology and Therapeutic Approaches. 川崎病血管炎：从诊断到病理生理学的新概念和治疗方法。
IF 22.1 1区 医学
Annual review of medicine Pub Date : 2026-01-01 Epub Date: 2025-10-29 DOI: 10.1146/annurev-med-050224-103456
Magali Noval Rivas, Moshe Arditi
{"title":"Kawasaki Disease Vasculitis: From Diagnosis to New Concepts in Pathophysiology and Therapeutic Approaches.","authors":"Magali Noval Rivas, Moshe Arditi","doi":"10.1146/annurev-med-050224-103456","DOIUrl":"10.1146/annurev-med-050224-103456","url":null,"abstract":"<p><p>Kawasaki disease (KD) is an acute, self-limiting vasculitis that primarily affects children under 5 years old. KD manifests as a persistent fever in the presence of mucocutaneous inflammation and lymphadenopathy, which in severe cases leads to the development of coronary artery aneurysms (CAAs). While early intervention with high-dose intravenous immunoglobulin and aspirin significantly lowers the risk of CAAs, up to 20% of patients with KD are resistant to intravenous immunoglobulin and face a substantially higher risk of developing coronary complications, highlighting the urgent need for more effective adjunctive and rescue therapies. Moreover, coronary abnormalities may persist after the apparent resolution of aneurysms, and cardiac complications extend into adolescence and adulthood. Murine models mimicking KD vasculitis have played a pivotal role in advancing our understanding of the disease's immunopathology, shedding light on the immune mechanisms driving its cardiovascular complications. Here, we summarize the current understanding of KD immunopathogenesis and its cardiovascular complications, as well as recent preclinical findings that are facilitating the development of novel therapeutic strategies, offering hope for improved management of KD in the future.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":"87-102"},"PeriodicalIF":22.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence to Guide Repurposing of Drugs. 人工智能将引导药物再利用。
IF 22.1 1区 医学
Annual review of medicine Pub Date : 2026-01-01 DOI: 10.1146/annurev-med-050224-122802
Zhimin Fu, Yuxin Yang, Mina K Chung, Feixiong Cheng
{"title":"Artificial Intelligence to Guide Repurposing of Drugs.","authors":"Zhimin Fu, Yuxin Yang, Mina K Chung, Feixiong Cheng","doi":"10.1146/annurev-med-050224-122802","DOIUrl":"10.1146/annurev-med-050224-122802","url":null,"abstract":"<p><p>With the pharmacokinetics, dosing, safety, and manufacturing of approved or investigational drugs already well-characterized, drug repurposing and repositioning offer emerging strategies to rapidly develop effective treatments for various challenging diseases. However, the growing mass of genetic and multiomics data has not been effectively explored by the drug repurposing community due to a lack of accurate approaches. This review aims to be an authoritative, critical, and accessible review and discussion of general interest to the drug repurposing community concerning the use of artificial intelligence (AI) and machine learning (ML) tools. Emerging questions include what is achievable with AI in this domain and what its impact will be, what AI and ML embrace, and how we, as geneticists, pharmacologists, and computational scientists, can contribute to the discovery of new, inexpensive, and affordable repurposable medicines. The fast growth of genetics and multiomics data (genomics, transcriptomics, proteomics, metabolomics, and radiomics) and electronic health records in diverse populations contributes to answering questions, including how to rapidly identify effective repurposable medicines, what a clinically meaningful effect size in trials is, and what the potential implications for precision medicine are. This review discusses AI and ML for drug repurposing in the context of genetics, multiomics, real-world data collection, and crowdsourcing of knowledge. We conclude by considering questions on how AI and ML methodologies can unite the diverse aspects of translational medicine for emerging treatment development in human-challenging diseases.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":"77 1","pages":"381-398"},"PeriodicalIF":22.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146058996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in Osteoporosis Therapeutics. 骨质疏松症治疗的最新进展。
IF 22.1 1区 医学
Annual review of medicine Pub Date : 2026-01-01 Epub Date: 2025-11-18 DOI: 10.1146/annurev-med-050124-040555
Anne Sophie Sølling, Bente L Langdahl, Felicia Cosman
{"title":"Recent Advances in Osteoporosis Therapeutics.","authors":"Anne Sophie Sølling, Bente L Langdahl, Felicia Cosman","doi":"10.1146/annurev-med-050124-040555","DOIUrl":"10.1146/annurev-med-050124-040555","url":null,"abstract":"<p><p>Postmenopausal osteoporosis is a chronic progressive disease related to estrogen deficiency at menopause, aging, and superimposed genetic and environmental factors. Many patients with osteoporosis are not diagnosed, and the majority are not treated. Current therapies for osteoporosis include antiresorptive treatments, including bisphosphonates, denosumab, and raloxifene, and osteoanabolic treatments, including teriparatide, abaloparatide, and romosozumab, which is a dual-action agent. Sequential therapies aim to optimize fracture prevention and bone density outcomes for long-term management. Recent guidelines have suggested categorical risk stratification and a goal-directed individualized therapy strategy. New treatments under investigation also hold promise for further improving bone health in postmenopausal osteoporosis.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":"433-448"},"PeriodicalIF":22.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145547932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR T Cell Toxicities and Emerging Treatment Strategies. CAR - T细胞的毒性和新兴的治疗策略。
IF 22.1 1区 医学
Annual review of medicine Pub Date : 2026-01-01 DOI: 10.1146/annurev-med-050224-120336
Amanda M Lulu, Erica Steele, Daniel W Lee
{"title":"CAR T Cell Toxicities and Emerging Treatment Strategies.","authors":"Amanda M Lulu, Erica Steele, Daniel W Lee","doi":"10.1146/annurev-med-050224-120336","DOIUrl":"https://doi.org/10.1146/annurev-med-050224-120336","url":null,"abstract":"<p><p>Having already revolutionized outcomes for relapsed or refractory B cell malignancies and multiple myeloma, chimeric antigen receptor (CAR) T cell therapy is on the cusp of significantly impacting those with solid tumors. However, antitumor response is frequently associated with acute toxicities due to immune hyperactivation, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hematotoxicity, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. We discuss the clinical presentations, evaluation, management, risk factors, and pathophysiologies of these toxicities and briefly describe emerging toxicity mitigation strategies.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":"77 1","pages":"219-237"},"PeriodicalIF":22.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146058965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunoglobulin A Nephropathy: New Treatment Options. 免疫球蛋白A肾病：新的治疗选择。
IF 22.1 1区 医学
Annual review of medicine Pub Date : 2026-01-01 DOI: 10.1146/annurev-med-043024-015024
Arun Rajasekaran, Dana V Rizk, Kirk N Campbell
{"title":"Immunoglobulin A Nephropathy: New Treatment Options.","authors":"Arun Rajasekaran, Dana V Rizk, Kirk N Campbell","doi":"10.1146/annurev-med-043024-015024","DOIUrl":"https://doi.org/10.1146/annurev-med-043024-015024","url":null,"abstract":"<p><p>Immunoglobulin A nephropathy (IgAN) remains the leading primary glomerular disease worldwide, with a majority of patients reaching kidney failure within their lifetimes. IgAN is a heterogeneous glomerular disorder characterized by mesangial deposition of galactose-deficient immunoglobulin A1 containing immune complexes that induce glomerular injury and nephron loss. The primary therapeutic goal in treating IgAN is reduction of nephron loss from the time of diagnosis. Management ideally incorporates interventions targeting both immunologic and nonspecific chronic kidney disease pathomechanisms. Multitargeted approaches that simultaneously target the production of pathogenic immunoglobulin A immune complexes, address the consequences of ongoing nephron loss, halt glomerular inflammation, and inhibit profibrotic signals in the glomerulus and tubulointerstitium will provide maximal benefit. Given significant advances in the understanding of disease pathogenesis and the acceptance of surrogate outcomes (including proteinuria reduction) for accelerated drug approval, there has been a plethora of pharmacological agents recently evaluated and approved to treat IgAN. This review highlights the latest therapeutic developments in the field.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":"77 1","pages":"267-279"},"PeriodicalIF":22.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146058988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions. 体细胞基因检测对癌症治疗决策的可及性。
IF 22.1 1区 医学
Annual review of medicine Pub Date : 2026-01-01 DOI: 10.1146/annurev-med-050124-082437
Madison Klavans, Fernanda B Musa, Marilyn Huang
{"title":"Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.","authors":"Madison Klavans, Fernanda B Musa, Marilyn Huang","doi":"10.1146/annurev-med-050124-082437","DOIUrl":"https://doi.org/10.1146/annurev-med-050124-082437","url":null,"abstract":"<p><p>Advances in cancer genomics have significantly influenced and improved oncologic treatments in recent years. Somatic genetic testing, which assesses for gene amplification and acquired mutations in tumor tissue, enables the identification of actionable mutations (i.e., biomarkers) to determine patients who may benefit from targeted therapies. Despite the progress made in somatic genetic testing, broad accessibility and adoption have been limited due to multifactorial barriers. Systematically addressing obstacles to somatic genetic testing is required to enhance availability, facilitate cancer treatments, and ultimately improve patient care.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":"77 1","pages":"207-218"},"PeriodicalIF":22.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146058998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis-Related Fibrosis: Therapeutic Options and Approaches to Treatment. 代谢功能障碍相关的脂肪变性肝病和代谢功能障碍相关的脂肪性肝炎相关纤维化：治疗选择和治疗方法
IF 22.1 1区 医学
Annual review of medicine Pub Date : 2026-01-01 DOI: 10.1146/annurev-med-050324-124753
Monica A Tincopa, Elizabeth K Speliotes, Luca Valenti, Rohit Loomba
{"title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis-Related Fibrosis: Therapeutic Options and Approaches to Treatment.","authors":"Monica A Tincopa, Elizabeth K Speliotes, Luca Valenti, Rohit Loomba","doi":"10.1146/annurev-med-050324-124753","DOIUrl":"https://doi.org/10.1146/annurev-med-050324-124753","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic liver disease impacting one-third of the adult population worldwide. MASLD has substantial associated morbidity and mortality, including progression to cirrhosis with the need for liver transplantation and development of hepatocellular carcinoma. Individuals with metabolic dysfunction-associated steatohepatitis (MASH), the more aggressive subtype of MASLD that includes hepatocyte injury, and stage 2 fibrosis or above are at the highest risk for adverse liver-related outcomes and overall mortality. Identification of high-risk individuals is key as these patients would benefit from directed pharmacotherapy for MASH. Additional directed pharmacotherapy agents are in development for MASH and hepatic fibrosis across various mechanisms of action. This review focuses on therapeutic options for and approaches to treatment in MASLD, including emerging agents.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":"77 1","pages":"103-115"},"PeriodicalIF":22.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146058940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microscopic Colitis: Evidence-Based Guide to Diagnosis and Management. 显微镜下结肠炎：基于证据的诊断和管理指南。
IF 22.1 1区 医学
Annual review of medicine Pub Date : 2026-01-01 DOI: 10.1146/annurev-med-050124-092157
Sara Ghoneim, Michael G Drage, Kristin E Burke
{"title":"Microscopic Colitis: Evidence-Based Guide to Diagnosis and Management.","authors":"Sara Ghoneim, Michael G Drage, Kristin E Burke","doi":"10.1146/annurev-med-050124-092157","DOIUrl":"https://doi.org/10.1146/annurev-med-050124-092157","url":null,"abstract":"<p><p>Microscopic colitis (MC), which predominately affects older adults, is a chronic inflammatory bowel disease characterized by watery diarrhea. Diagnosis relies on histological examination, as there are no established biomarkers to facilitate noninvasive diagnosis, and endoscopic findings are typically unremarkable. MC is classified into subtypes of lymphocytic and collagenous colitis. First-line therapy is budesonide (9 mg/day for 6-8 weeks), which induces remission effectively. However, relapse rates are high, necessitating alternative treatment strategies. Long-term maintenance strategies include low-dose budesonide, bile salt binders, antidiarrheals, and advanced therapies for refractory cases.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":"77 1","pages":"253-266"},"PeriodicalIF":22.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146058949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A New Era in the Medical Management of Obesity. 肥胖症医学管理的新时代
IF 22.1 1区 医学
Annual review of medicine Pub Date : 2026-01-01 DOI: 10.1146/annurev-med-043024-125437
Florence Porterfield, Anam Fatima, Brunna Boaventura, Ayush Madhar, Gitanjali Srivastava, Fatima Cody Stanford
{"title":"A New Era in the Medical Management of Obesity.","authors":"Florence Porterfield, Anam Fatima, Brunna Boaventura, Ayush Madhar, Gitanjali Srivastava, Fatima Cody Stanford","doi":"10.1146/annurev-med-043024-125437","DOIUrl":"https://doi.org/10.1146/annurev-med-043024-125437","url":null,"abstract":"<p><p>A new era in obesity management is emerging, characterized by the development of more effective treatments and healthcare strategies. A paradigm shift in obesity care calls for a more integrated, community-based approach that bridges the gap between medical management and bariatric surgery. This review explores important pillars related to obesity management, encompassing aspects related to the pathophysiology of the disease; treatments related to behavioral, nutritional, pharmacotherapeutic, and surgical approaches; and stigma mitigation.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":"77 1","pages":"131-146"},"PeriodicalIF":22.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146058951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential Health Risks of Artificial Sweeteners. 人造甜味剂的潜在健康风险。
IF 22.1 1区 医学
Annual review of medicine Pub Date : 2026-01-01 Epub Date: 2025-10-31 DOI: 10.1146/annurev-med-043024-012626
Maria Effenberger, Herbert Tilg
{"title":"Potential Health Risks of Artificial Sweeteners.","authors":"Maria Effenberger, Herbert Tilg","doi":"10.1146/annurev-med-043024-012626","DOIUrl":"10.1146/annurev-med-043024-012626","url":null,"abstract":"<p><p>Artificial sweeteners are widely used worldwide, yet their potential health effects remain a topic of debate. Recent studies suggest that artificial sweeteners, both nutritive and nonnutritive, may stimulate appetite, leading to increased caloric intake, a higher body mass index, and a greater risk of obesity. These metabolic changes are associated with an elevated risk of type 2 diabetes and cardiovascular diseases. Moreover, emerging preclinical evidence indicates that artificial sweeteners may influence cancer biology, potentially affecting tumor progression. This review examines the impact of artificial sweeteners on metabolic health, cardiovascular risk, and carcinogenesis, emphasizing the need for further research to clarify their long-term safety and health implications.</p>","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":"117-130"},"PeriodicalIF":22.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145421071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书